SPY
736.53
+0.17%
QQQ
657.50
+0.21%
BTC/USD
75,892.96
+0.19%
DIA
512.52
+0.06%
GLD
373.37
+0.23%
TLT
81.85
−0.09%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
GRI Bio Inc
GRI
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.88
0.33
21.29%
Last update: Nov 6, 6:03 PM
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Dividends
Compare
Stock Report
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
GRI Bio Financials
GRI Bio (GRI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.91) by 78.89 percent. This is a 99.01 percent increase over losses of $(162.40) per share from the
Benzinga Newsdesk
PRO
GRI Bio Q3 EPS $(1.28) Misses $(0.93) Estimate
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.93) by 37.63 percent. This is a 88.79 percent increase over losses of $(11.42) per share from the
Benzinga Newsdesk
PRO
GRI Bio Q2 EPS $(1.31), Inline
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.31) per share which met the analyst consensus estimate. This is a 97.88 percent increase over losses of $(61.85) per share from the same period last year.
Benzinga Newsdesk
Crude Oil Falls 1%; Meta Earnings Top Views
Avi Kapoor
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings
Avi Kapoor
PRO
GRI Bio Q1 EPS $(5.80) Misses $(4.11) Estimate
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(5.80) per share which missed the analyst consensus estimate of $(4.11) by 41.12 percent. This is a 94.26 percent increase over losses of $(101.05) per share from the
Benzinga Newsdesk
